Santander Sees Higher Profitability in 2024 After 4Q Net Profit Jump
By Helena Smolak
Banco Santander said it expects higher profitability in 2024 after the bank reported an increased net profit for the fourth quarter.
The Spanish lender said Wednesday it is targeting mid-single digit revenue growth, a fully-loaded common equity Tier 1 ratio above 12% and a return on tangible equity--a key measure of profitability--of 16% in 2024. For 2023, Santander's return on tangible equity stood at 15.6%.
Santander said net profit for the fourth quarter was 2.93 billion euros ($3.18 billion) compared with EUR2.29 billion reported for the year-earlier period.
Total revenue for the fourth quarter grew to EUR14.55 billion from EUR13.52 billion a year before, with net interest income--the difference between what banks earn on loans and pay clients for deposits--coming in at EUR11.12 billion.
Analysts polled by Visible Alpha expected Santander's fourth-quarter net profit to be EUR2.61 billion on total revenue of EUR14.58 billion.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
January 31, 2024 01:39 ET (06:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks